These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36333206)

  • 1. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.
    Rosenkranz S; Pausch C; Coghlan JG; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Delcroix M; Ghofrani HA; Ewert R; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Scelsi L; Neurohr C; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Lange TJ; Olsson KM; Hoeper MM; Opitz C
    J Heart Lung Transplant; 2023 Jan; 42(1):102-114. PubMed ID: 36333206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Rosenkranz S; Lange TJ
    J Heart Lung Transplant; 2022 Jul; 41(7):971-981. PubMed ID: 35430147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Park DH; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Lange TJ; Rosenkranz S
    Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34737226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
    Hoeper MM; Dwivedi K; Pausch C; Lewis RA; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Park DH; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Lange TJ; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Swift AJ; Thompson AAR; Elliot CA; Rosenkranz S; Condliffe R; Kiely DG; Halank M
    Lancet Respir Med; 2022 Oct; 10(10):937-948. PubMed ID: 35777416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
    Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
    Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up.
    Xanthouli P; Koegler M; Marra AM; Benjamin N; Fischer L; Eichstaedt CA; Harutyunova S; Nagel C; Grünig E; Egenlauf B
    Respir Res; 2020 May; 21(1):127. PubMed ID: 32448256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension.
    Sahay S; Villasmil Hernandez N; Wang F; Wooten M; Nguyen DT; Fauvel C; Benza R; Graviss EA
    Chest; 2024 Aug; 166(2):373-387. PubMed ID: 38447640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension.
    Mauritz GJ; Rizopoulos D; Groepenhoff H; Tiede H; Felix J; Eilers P; Bosboom J; Postmus PE; Westerhof N; Vonk-Noordegraaf A
    Am J Cardiol; 2011 Dec; 108(11):1645-50. PubMed ID: 21890089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
    Fritz JS; Blair C; Oudiz RJ; Dufton C; Olschewski H; Despain D; Gillies H; Kawut SM
    Chest; 2013 Feb; 143(2):315-323. PubMed ID: 22814814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.
    Hoeper MM; Pausch C; Grünig E; Klose H; Staehler G; Huscher D; Pittrow D; Olsson KM; Vizza CD; Gall H; Benjamin N; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Rosenkranz S; Ewert R; Kaemmerer H; Lange TJ; Kabitz HJ; Skowasch D; Skride A; Jureviciene E; Paleviciute E; Miliauskas S; Claussen M; Behr J; Milger K; Halank M; Wilkens H; Wirtz H; Pfeuffer-Jovic E; Harbaum L; Scholtz W; Dumitrescu D; Bruch L; Coghlan G; Neurohr C; Tsangaris I; Gorenflo M; Scelsi L; Vonk-Noordegraaf A; Ulrich S; Held M
    J Heart Lung Transplant; 2020 Dec; 39(12):1435-1444. PubMed ID: 33082079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey.
    Yaylalı YT; Başarıcı I; Kılıçkıran Avcı B; Meriç M; Sinan ÜY; Şenol H; Küçükoğlu MS; Öngen Z
    Anatol J Cardiol; 2019 Jun; 21(6):322-330. PubMed ID: 31142721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.
    Rosenkranz S; Ghofrani HA; Hoeper MM; Langleben D; Hegab S; Rahner C; Richard JF; McLaughlin VV
    J Heart Lung Transplant; 2024 Sep; ():. PubMed ID: 39236972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
    Hendriks PM; van de Groep LD; Veen KM; van Thor MCJ; Meertens S; Boersma E; Boomars KA; Post MC; van den Bosch AE
    Am Heart J; 2022 Aug; 250():34-44. PubMed ID: 35533723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension.
    Stolfo D; Barbisan D; Ameri P; Lombardi CM; Monti S; Driussi M; Zovatto IC; Gentile P; Howard L; Toma M; Pagnesi M; Collini V; Bauleo C; Guglielmi G; Adamo M; D'Angelo L; Nalli C; Sciarrone P; Moschella M; Zorzi B; Vecchiato V; Milani M; Di Poi E; Airò E; Metra M; Garascia A; Sinagra G; Lo Giudice F
    J Heart Lung Transplant; 2023 Aug; 42(8):1082-1092. PubMed ID: 37005100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
    Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
    Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
    Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
    BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension.
    Andreassen AK; Wergeland R; Simonsen S; Geiran O; Guevara C; Ueland T
    Am J Cardiol; 2006 Aug; 98(4):525-9. PubMed ID: 16893710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.